Concepedia

Umakanth Vudumula

UV

Statistics

Publications

6

Citations

109

H-Index

6

Active since

2011

Affiliations

Novartis (India)(Current)

Indian Institute of Technology Guwahati

Novartis (Ireland)

Novartis (Switzerland)

Umakanth Vudumula is an author at Novartis (India) specializing in pharmacy, pharmacoeconomics, and cost-effectiveness modeling.

Publications per year

2011–2022

6

Publications

6

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

R Mahon, A Lang, Pamela Vo et al. · PharmacoEconomics · 2021 · 35 citations

Pharmacy, Neurology, Pharmacoeconomics +11

Tuning the bactericidal repertoire and potency of quinoline-based amphiphiles for enhanced killing of pathogenic bacteria

Umakanth Vudumula, Manab Deb Adhikari, Bimlesh Ojha et al. · RSC Advances · 2012 · 21 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland

Nadine Schur, Kapil Gudala, Umakanth Vudumula et al. · PharmacoEconomics · 2021 · 17 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Eytan M. Stein, Jipan Xie, Emilie D. Duchesneau et al. · PharmacoEconomics · 2018 · 14 citations

Pharmacy, Oncology, Pharmacoeconomics +13

Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK

Stephen Montgomery, F Woodhouse, Umakanth Vudumula et al. · Journal of Medical Economics · 2022 · 12 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16

1–5 of 6